Mutations in DNA Repair Genes Affect Survival in Prostate Cancer

According to a noteworthy prostate cancer study at ESMO 2017, inherited mutations in DNA repair genes were associated with shorter survival in metastatic prostate cancer resistant to hormonal therapy (castration).
Of cancers, 10 percent are caused by inherited (germline) mutations. Most of these mutations occur in DNA repair genes. Although some mutations in DNA repair genes have been associated with shorter survival in prostate cancer, in metastatic prostate cancer resistant to hormone therapy there had been no study of the relationship between germline mutations and life-prolonging treatments. ESMO 2017 presented a study observing that hormone therapy-resistant prostate cancer patients with mutations in DNA repair genes had a poor disease course and survival.
You May Be Interested In:
The multicenter observational PROREPAIR-Bstudy included patients with newly diagnosed metastatic (stage 4) hormone therapy-resistant resistant prostate cancer and unknown germline mutation status. Between January 2013 and April 2016, from 36 institutions in Spain, patients treated with abiraterone, enzalutamide, docetaxel, cabazitaxel and Ra-223 totaled 419 study participants. Researchers analyzed samples collected from these patients for inherited mutations in BRCA1, BRCA2, ATM and PALB2 genes, identifying the effects of these mutations on disease development and first-line life-prolonging treatments.
According to the Research Results
- A total of 26 patients were identified as carriers of inherited gene mutations. Of these, 14 carried mutations in BRCA2, 8 in ATM and 4 in BRCA1.
- In carriers, the interval from starting androgen-lowering treatment (abiraterone and enzalutamide) to metastatic disease was shorter. It was 23.7 months in carriers and 26.7 in noncarriers. In BRCA2 carriers, the interval was 18 months.
- Survival was shorter in carriers than in noncarriers. It was 28.5 months in carriers and 36 months in noncarriers. In BRCA2 carriers, survival was particularly short (17.4 months).
- Among patients receiving taxane chemotherapy (docetaxel and cabazitaxel), disease-free survival was 7.8 months in carriers and 7.1 months in noncarriers.
In conclusion, no significant difference was found when comparing disease-free survival between inherited mutation carriers and noncarriers. However, the disease course is particularly poor in BRCA2 carriers.
You may be interested in:
Sources
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.